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CASE REPORT
Imaging of primitive neuroectodermal tumor (PNET) by 
technetium-99m tetrofosmin
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Abstract
Purpose. Tc-99m tetrofosmin launched for myocardial studies has recently also shown a good detectability for several tumors.
Data on PNET imaging by Tc-99m tetrofosmin are not yet available.
Patient and method. In the case of a 21-year-old man suffering from pelvis PNET, Tc-99m tetrofosmin scintigraphy was
performed additionally to CT and MRI.
Results. The gluteal and iliac tumor masses were visualized by Tc-99m tetrofosmin according to the CT and MRI results.
Discussion. Imaging with Tc-99m tetrofosmin could provide additional information to the available conventional radiological
imaging modalities for diagnosis of PNET, and could be a useful tool for the restaging of the primary tumor.
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Patient
In October 1999 a 21-year-old man presented with a
painful mass in the right gluteal region which had
developed within the last 4 weeks. Previous medical
history was without any major events except for lower
back pain persisting for the last 12 months despite
conservative treatment. 
Physical examination revealed a subfebrile patient
with a firm, egg-sized right gluteal mass, painful loss
of motion in the right hip joint and paresthesia on the
ventral and medial part of the right femur. Aside from
leukocytosis and an elevated C-reactive protein, lab-
oratory testing was unremarkable. 
A pelvic CT scan showed a spindle-shaped mass in
the right greatest gluteal muscle and a second mass
originating in  the  right iliac  muscle displacing the
right  ureter  and  psoas  muscle.  In  addition,
hepatomegaly  was  found, and  osteomyelitis of  the
right  iliac  bone  was  suspected.  Pathohistological
examination of a consecutive incisional biopsy of the
gluteal mass diagnosed a primitive neuroectodermal
tumor (PNET). Staging examinations, including cra-
nial  and  thoracic  CT  scan  as  well  as  bone  scan,
revealed multiple pulmonary lesions (2–5 mm) in the
right lower lobe, a left-sided pleural effusion and dif-
fuse infiltration of the lower vertebral spine and pel-
vis. MRI (Fig. 1) of the pelvis demonstrated that the
gluteal  and  iliac  masses  were  infiltrating  the  right
femur,  hip  joint,  lower  lumbar  vertebrae  and  the
sacrum with consecutive narrowing of the neurofor-
amen L5/S1.
Method and results
Technetium-99m tetrofosmin imaging and analysis
Planar  and  single  photon  emission  tomography
(SPECT) acquisitions were performed with a large
Fig.  1.  Enhanced  T1  SE  sequence  shows  inhomogeneous
enhancement of the tumor in the gluteal area (right side); the
bladder is filled with contrast agent.216 G. Karanikas et al.
field-of-view  double-headed  gamma  camera  (Sie-
mens ICON) equipped with a low-energy, parallel-
hole  collimator.  Imaging  was  done  10  min  after
administration of 580 MBq technetium-99m tetro-
fosmin. SPECT imaging of the pelvic region was per-
formed subsequently after the planar acquisition. 
Scintigraphic data were reconstructed after prefil-
tering with a low pass filter using filtered backprojec-
tion and a ramp filter. Final evaluation of all scans
was done from coronal, sagittal and transaxial slices.
Evaluation  was  performed  independently  by  two
nuclear medicine physicians with experience in the
interpretation of tetrofosmin studies.
Augmented technetium-99m tetrofosmin accumu-
lation was obtained in the left pelvic and hip region
(Fig. 2). The uptake of the tracer correlated well with
the  gluteal  and  iliac  masses  as  described by  MRI
(Fig. 3.). 
The patient was assigned to receive two cycles of
chemotherapy according to the Euro-Ewing proto-
col, in the course of which he repeatedly developed
febrile neutropenia and renal failure which were con-
trolled by haematopoetic growth factors, antibiotics
and diuretics. In January 2000 restaging revealed a
marked progression of both, pulmonary and pelvic
lesions and a new lesion in the thoracic spine com-
pressing  the  right  neuroforamen  T7/T8.  Subse-
quently, the patient was assigned to receive palliative
irradiation of the thoracic and lumbar spine and the
right pelvis. However, his clinical status deteriorated
rapidly  and  2  weeks  later,  in  February  2000,  our
patient died due to his underlying disease. 
Discussion
Various radiopharmaceuticals have been explored for
use in detection and characterization of musculoskel-
etal  sarcomas.  The  choice  of  an  adequate  tumor-
depicting radiopharmaceutical in the clinical situa-
tion is not always obvious in the expanding field of
nuclear oncology. Tetrofosmin, a lipophilic cationic
diphosphine,  originally  developed  for  myocardial
perfusion  imaging,  has  proved  to  be  an  excellent
tumor-imaging agent, accumulating in thyroid and
breast cancers, and recently in a variety of tumors,
showing a sensitivity of 95% and above, as well as a
quite high specificity.1–3 Recently, technetium-99m
tetrofosmin uptake by several musculoskeletal sarco-
mas of the extremities or pelvis has been examined.4
In  our  case  report,  a  primitive  neuroectodermal
tumor  (PNET)  was  imaged  by  technetium-99m
tetrofosmin,  giving  a  good  correlation  with  other
imaging  modalities,  such  as  CT  and  MRI.  Lung
metastases were not visualized, probably because of
their small size. PNET imaging by Tc-99m tetrofos-
min could provide additional information in the stag-
ing  process  and  give,  furthermore,  valuable
information in the restaging process of the tumor.
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Fig. 2. The technetium-99m tetrofosmin scintigraphy (in pos-
terior view) reveals gluteal and iliac tumor masses in good cor-
relation with MRI. Physiological accumulation of the tracer in 
gastrointestinal tract and bladder. 
Fig 3. The SPECT image (sagittal) shows the tumor with the 
necrotic masses.